YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II/III clinical study for YOLT-202, its in vivo gene editing drug for alpha-1 antitrypsin deficiency (AATD). The first-in-class therapeutic, based on YolTech’s proprietary YolBE next-generation adenine base editor, enables precise correction of the SERPINA1 PiZ mutation to normal PiM in hepatocytes, restoring functional AAT protein expression while avoiding bystander editing. With prior FDA Orphan Drug Designation, YOLT-202 represents a potential “one-shot cure” for the genetic disorder affecting 95% of severely affected PiZZ genotype patients.
Regulatory Milestone
Item
Detail
Agency
U.S. Food and Drug Administration (FDA)
Approval Type
Phase II/III clinical trial authorization (IND)
Product
YOLT-202
Drug Class
In vivo gene editing therapy (adenine base editor)
Platform
YolBE – next-generation adenine base editor (self-developed)
Target
SERPINA1 PiZ locus (Glu342Lys mutation)
Mechanism
Converts PiZ mutation to normal PiM; restores functional AAT protein in hepatocytes
Indication
Alpha-1 antitrypsin deficiency (AATD)
Study Design
Open-label, single-dose expansion Phase II/III
Prior Designation
FDA Orphan Drug Designation (ODD)
Developer
YolTech Therapeutics (China-based)
Approval Date
16 Mar 2026
Gene Editing Technology & Differentiation
Attribute
YOLT-202 / YolBE Platform Specification
Editor Class
Adenine base editor (ABE) – next-generation
Precision
Single-base conversion (A→G) at PiZ locus
Target Locus
SERPINA1 PiZ (Glu342Lys) → PiM (normal)
Bystander Editing
Almost completely avoided – key safety advantage
Delivery
In vivo (liver-directed)
Therapeutic Goal
Permanent correction; “one-shot cure” potential
Cell Type
Hepatocytes (AAT production site)
Scientific Rationale:
AATD Genetics: SERPINA1 mutations → misfolded AAT protein → polymerization → lung (COPD) and liver damage
PiZ Allele: Most common severe mutation (Glu342Lys); >95% of severe patients are PiZZ homozygous
Base Editing Advantage: Direct DNA correction without double-strand breaks (vs. CRISPR-Cas9); reduced off-target risk
Disease Context & Unmet Need
Parameter
Alpha-1 Antitrypsin Deficiency (AATD)
Genetics
SERPINA1 gene mutations; Z and S alleles most common
Pathophysiology
Misfolded AAT protein polymerizes; trapped in hepatocytes; low circulating AAT → lung elastase damage
>95% of severely affected patients; focus of YOLT-202 development
Standard of Care
Weekly IV AAT augmentation (Prolastin); lung/liver transplant for end-stage disease
Unmet Need
No curative therapy; augmentation expensive and inconvenient; progressive organ damage despite treatment
Strategic Context & Competitive Landscape
Factor
Implication
Gene Editing Race
Intellia (NTLA-2002, NTLA-3001), Beam Therapeutics (BEAM-302) also developing AATD base editors; YolTech China-based but U.S.-first development strategy
In Vivo Advantage
Direct liver delivery vs. ex vivo cell editing; eliminates cell therapy manufacturing complexity
Bystander Avoidance
YolBE precision differentiates from earlier base editors; safety profile critical for regulatory approval
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase II/III outcomes, base editing durability, and competitive positioning for YOLT-202. Actual results may differ due to in vivo editing efficiency challenges, immune responses to delivery vectors, and competitive dynamics with other gene editing approaches.-Fineline Info & Tech
By Fineline Cube